Vertex Pharmaceuticals Incorporated remains a top Buy with a strong cystic fibrosis franchise, innovative pipeline, and cell therapies. Click for my VRTX update.

PGIM Jennison Health Sciences Fund’s Q1 2025 letter highlights mixed sector returns, with Vertex Pharmaceuticals in focus.

The hybrid decentralized exchange has confirmed that it will shut down its platform on Arbitrum and move to Kraken-backed L2 ...

"Vertex reports long-term results for Casgevy in sickle cell and thalassaemia" was originally created and published by ...